HROW

#2212
Harrow, Inc. - Common Stock
38.2 9 USD
-0.02%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
38.07
38.36
Year Range
28.54
54.85
Daily Change
-1.95%
Monthly Change
-2.20%
6 month change
-1.85%
Year Change
-1.82%
Previous Close
39.0 5
Open
38.3 4
Low
38.0 7
High
38.3 6
Volume
248
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
HARROW, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
HARROW, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
HARROW, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
HARROW, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
HARROW, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
HARROW, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
HARROW, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
HARROW, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
HARROW, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
HARROW, INC. current report, Q1 FY2026
8-K

HARROW, INC. current report, 26 January 2024

Full document

Harrow, Inc. (HROW) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Harrow, Inc. on January 29, 2024, covering events that occurred on January 26, 2024. The Company is a biopharmaceutical entity incorporated in Delaware, with principal executive offices in Nashville, Tennessee. The filing primarily addresses corporate governance changes regarding the Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of new directors and does not contain financial statements or operational metrics for the period.

Material Changes

The Board of Directors expanded its size from four members to six members. Two new directors were elected effective immediately:

  • Adrienne L. Graves, Ph.D.: Brings extensive experience in ophthalmology, pharmaceutical development, and commercialization. Formerly President and CEO of Santen Inc. and board member of Ocular Therapeutix, Nicox S.A., and Surface Ophthalmics.
  • Lauren P. Silvernail: A financial and strategic advisor with significant experience as a CFO in the aesthetic medicines sector (Evolus, Revance Therapeutics, ISTA Pharmaceuticals). Currently serves on the board of Harpoon Therapeutics and Nicox S.A.

Neither new director has been assigned to specific Board committees at this time.

Guidance, Outlook, and Risks

The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific business risks or contingencies. The only noted contingency is the standard indemnification agreement entered into by the new directors, which may require the Company to indemnify them for expenses, judgments, fines, and settlement amounts arising from their service.

Key Facts for Investor Verification

  • Verify the impact of the expanded Board on strategic direction, particularly given the new directors' backgrounds in ophthalmology and finance.
  • Confirm the timing of committee assignments for Dr. Graves and Mrs. Silvernail, as none were named in this filing.
  • Review the definitive proxy statement filed on April 28, 2023, for details on the non-employee director compensation policy applicable to the new appointees.
  • Check subsequent filings for any financial updates, as this 8-K contains no financial data.

News